An observational study in Renal Cell Carcinoma (RCC), sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Observational
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is one of 4 that started in 2026, is one of 9 observational ones, and was the 42nd registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, France and 2 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 5 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 119 across the 33 interventional studies, 297 across the 9 observational. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
2 of the studies in Carcinoma, Renal Cell by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT06764771Bristol-Myers SquibbA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma who start first-line systemic therapy.
Adults (≥18 years) in Spain with a confirmed diagnosis of advanced or metastatic renal cell carcinoma who initiate first-line systemic therapies from January 1, 2019, to December 31, 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with advanced or metastatic renal cell carcinoma who initiated a first-line systemic regimen during the study period and were classified as International Metastatic RCC Database Consortium intermediate- or poor-risk.
Drug: First-line systemic regimens
First-line systemic regimens for advanced or metastatic renal cell carcinoma include: nivolumab plus ipilimumab, axitinib plus avelumab, axitinib plus pembrolizumab, lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, cabozantinib, tivozanib, sunitinib, and pazopanib
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., CabozantinibStudies of CabozantinibCabozantinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Overall survival from index date to death from any cause
Time frame: Up to 7 years
Progression-free survival from index date to progression or death
Time frame: Up to 7 years
Objective response rate (ORR) based on documented complete or partial response
Objective response rate is defined as the proportion of participants with documented partial response or complete response based on oncology or radiology electronic medical record entries.
Time frame: Up to 7 years
Duration of response (DoR) from first documented response to progression or death
Time frame: Up to 7 years
Time to response (TRR) from index date to first documented response
Time frame: Up to 7 years
Treatment-free survival (TFS) after discontinuation of first-line treatment
Treatment-free survival is defined as the time from documented discontinuation of first-line treatment to the earliest of initiation of any subsequent systemic anti-cancer therapy or death.
Time frame: Up to 7 years
Outcome 6 Title Number of participants with adverse events
Time frame: Up to 7 years
Healthcare resource utilization during follow-up
Healthcare resource utilization includes all-cause hospitalizations, emergency room visits, outpatient visits, diagnostic procedures including computed tomography, magnetic resonance imaging, and laboratory assessments, and systemic therapy administrations.
Time frame: Up to 7 years
Direct healthcare costs during follow-up
Direct healthcare costs are estimated using a unit-cost method applied to medications and healthcare resource utilization. Cost categories include medication costs, hospital service costs, outpatient care costs, diagnostic procedure costs, supportive care costs, and total direct cost.
Time frame: Up to 7 years
Treatment duration from first-line therapy dose to discontinuation, switch, or end of follow-up
Time frame: Up to 7 years
Number of ipilimumab doses administered to participants receiving first-line nivolumab plus ipilimumab
Time frame: Up to 7 years
Number of participants that discontinue treatment
Time frame: Up to 7 years
Subsequent systemic therapy regimens prescribed after first-line treatment discontinuation
Time frame: Up to 7 years
Number of participants with prior adjuvant anti-programmed cell death protein 1 (PD-1) exposure
Time frame: Up to 12 months prior to Index Date
Plan to share: No
Ran from Jul 2026 to primary completion in Sep 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.